secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surface Oncology, Inc. (—)
CIK:        0001718108
Form:       8-K
Filed at:   2023-07-10T23:59:59+00:00
Accession:  0001193125-23-184004
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Surface Oncology transfers to Nasdaq Capital Market; gets extended compliance period to Jan 2, 2024
--------------------------------------------------------------------------------

- Stock transferred from Nasdaq Global Market to Capital Market effective July 10, 2023; ticker remains SURF.
- Extended compliance period until January 2, 2024 to regain $1.00 minimum bid price.
- Company will consider reverse stock split to regain compliance; no assurance of success.
- Previously disclosed bid price deficiency on Jan 6, 2023; initial 180-day period expired July 5, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1718108/000119312523184004/0001193125-23-184004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1718108/000119312523184004/d533683d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-184004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer